Oxidative stress-related risk of the multiple sclerosis development

Marija Vasic; Aleksandra Topic; Bojan Markovic; Neda Milinkovic; Evica Dincic

doi:10.5937/jomb0-37546

Marija Vasic MMA
Aleksandra Topic Universitiy of Belgrade-Faculty of Pharmacy
Bojan Markovic Universitiy of Belgrade-Faculty of Pharmacy
Neda Milinkovic Universitiy of Belgrade-Faculty of Pharmacy
Evica Dincic Military Medical Academy

DOI: https://doi.org/10.5937/jomb0-37546

Keywords: multiple sclerosis, oxidative stress, oxidative stress index, 8-oxo-7,8-dihydro-2´-deoxyguanosine, total antioxidant status, total oxidative status

Abstract

Background: Multiple sclerosis (MS) is characterized by inflammation, demyelination and axonal degeneration. Oxidative stress (OS) plays a significant role in the pathogenesis of the disease. The aim of the study was to examine the association between OS and smoking on the MS development.

Methods: The study included 175 patients with relapsing-remitting multiple sclerosis (RRMS) (76 males, 99 females) and 254 healthy subjects (81 males and 173 females). Oxidative stress biomarkers in serum, Total Antioxidant Status (TAS) and Total Oxidative Status (TOS) were determined spectrophotometrically. Oxidative Stress Index (OSI) was calculated as the ratio of TOS and TAS. Urinary 8-oxo-7,8-dihydro-2´-deoxyguanosine were determined by HPLC-MS/MS and expressed as 8-oxodG/creatinine.

Results: In females with RRMS were higher TOS, OSI and 8-oxodG/creatinine than in females in control group. The group of males with RRMS had lower level of TAS than the males in control group. Higher levels of 8-oxodG/creatinine was obtained in active, passive and former smokers with RRMS than in control group with the same exposition to tobacco smoke. Independent predictors of MS are passive smoking, increased OSI and increased levels of urinary 8-oxodG/creatinine.

Conclusion: Our results demonstrate that the OS parameters should be included in the assessment of the risk for MS development. Due to the more sensitivity to oxidative stress, females may be at higher risk of MS development. This data indicates the importance of introducing the antioxidant therapy as a complementary treatment in patients with RRMS.

References

References
1. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020; 26:1816-1821.
2. GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:269-285.
3. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014; 15; 83:278-286.
4. Tobore TO. Oxidative/Nitroxidative Stress and Multiple Sclerosis. J Mol Neurosci. 2021; 71:506-514.
5. Ortiz GG, Pacheco-Moisés FP, Bitzer-Quintero OK, Ramírez-Anguiano AC, Flores-Alvarado LJ, Ramírez-Ramírez V, et al. Immunology and oxidative stress in multiple sclerosis: clinical and basic approach. Clin Dev Immunol. 2013; 2013:708659.
6. Phaniendra A, Jestadi DB, Periyasamy L. Free radicals: properties, sources, targets, and their implication in various diseases. Indian J Clin Biochem. 2015; 30:11–26.
7. Islam MT. Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders. Neurol Res. 2017; 39:73-82.
8. Wingerchuk DM. Smoking: effects on multiple sclerosis susceptibility and disease progression. Ther Adv Neurol Disord. 2012; 5(1):13-22.
9. Shirani A, Tremlett H. The effect of smoking on the symptoms and progression of multiple sclerosis: a review. J Inflamm Res. 2010; 3:115-26.
10. Arneth B, Multiple Sclerosis and Smoking. Am J Med. 2020; 133:783-788
11. Hedström AK, Hillert J, Olsson T, Alfredsson L. Smoking and multiple sclerosis susceptibility. Eur J Epidemiol. 2013; 28:867-874.
12. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005; 38: 1103-1011.
13. Cooke MS, Evans MD. 8-Oxo-deoxyguanosine: reduce, reuse, recycle? Proc Natl Acad Sci USA.2007; 104:13535‒13536.
14. Aydemir Y, Aydemir Ö, Şengül A, Güngen AC, Çoban H, Taşdemir C, et al. Comparison of oxidant/antioxidant balance in COPD and non-COPD smokers. Heart Lung. 2019; 48:566-569.
15. Topic A, Francuski D, Markovic B, Stankovic M, Dobrivojevic S, Drca S, et al. Gender-related reference intervals of urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine determined by liquid chromatography-tandem mass spectrometry in Serbian population. Clin Biochem. 2013; 46:321-326.
16. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005; 38:1103‒1111.
17. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 2004; 37:277‒285.
18. Tobore TO. Oxidative/Nitroxidative Stress and Multiple Sclerosis. J Mol Neurosci. 2021; 71:506-514.
19. Padureanu R, Albu CV, Mititelu RR, Bacanoiu MV, Docea AO, Calina D, et al. Oxidative Stress and Inflammation Interdependence in Multiple Sclerosis. J Clin Med. 2019; 8:1815.
20. Haider L. Inflammation, Iron, Energy Failure, and Oxidative Stress in the Pathogenesis of Multiple Sclerosis. Oxid Med Cell Longev. 2015; 2015:725370.
21. Toncev G, Miletic Drakulic S, Knezevic Z, Boskovic Matic T, Gavrilovic A, Toncev S, et al. Prevalence of multiple sclerosis in the Serbian district Sumadija. Neuroepidemiology. 2011; 37:102-106.
22. Kirbas A, Kirbas S, Anlar O, Efe H, Yilmaz A. Serum paraoxonase and arylesterase activity and oxidative status in patients with multiple sclerosis. J Clin Neurosci. 2013; 20:1106-1109.
23. Acar A, Ugur Cevik M, Evliyaoglu O, Uzar E, Tamam Y, Arıkanoglu A, Yucel Y, et al. Evaluation of serum oxidant/antioxidant balance in multiple sclerosis. Acta Neurol Belg. 2012;112:275-280.
24. Souliotis VL, Vlachogiannis NI, Pappa M, Argyriou A, Ntouros PA, Sfikakis PP. DNA Damage Response and Oxidative Stress in Systemic Autoimmunity. Int J Mol Sci. 2019; 20;21:55.
25. Korkmaz KS, Butuner BD, Roggenbuck D. Detection of 8-OHdG as a diagnostic biomarker. J Lab Precis Med; 2018:95.
26. Mesaros C, Arora JS, Wholer A, Vachani A, Blair IA. 8-Oxo-2'-deoxyguanosine as a biomarker of tobacco-smoking-induced oxidative stress. Free Radic Biol Med. 2012; 1;53: 610-617.
27. Miller ED, Dziedzic A, Saluk-Bijak J, Bijak M. A. A Review of Various Antioxidant Compounds and their Potential Utility as Complementary Therapy in Multiple Sclerosis. Nutrients. 2019; 5;11:1528.
28. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008; 71:129– 135.
29. Bove R, Chitnis T. The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler. 2014; 20:520-526.
30. Antulov R, Weinstock-Guttman B, Cox JL, Hussein S, Durfee J, Caiola C, et al. Gender-related differences in MS: a study of conventional and nonconventional MRI measures. Mult Scler. 2009; 15:345–354.
31. Hedström AK, Olsson T, Alfredsson L. Smoking is a major preventable risk factor for multiple sclerosis. Mult Scler. 2016; 22:1021-1026.
32. Ayaori M, Hisada T, Suzukawa M, Yoshida H, Nishiwaki M, Ito T, et al. Plasma levels and redox status of ascorbic acid and levels of lipid peroxidation products in active and passive smokers. Environ Health Perspect. 2000; 108:105-108.
33. Dietrich M, Block G, Norkus EP, Hudes M, Traber MG, Cross CE, et al. Smoking and exposure to environmental tobacco smoke decrease some plasma antioxidants and increase γ-tocopherol in vivo after adjustment for dietary antioxidant intakes. Am J Clin Nutr. 2003; 77:160–166.
34. Sundström P, Nyström L, Hallmans G. Smoke exposure increases the risk for multiple sclerosis. Eur J Neurol. 2008; 15:579-583.
35. Hewagama A, Patel D, Yarlagadda S, Strickland FM, Richardson BC. Stronger inflammatory/cytotoxic T-cell response in women identified by microarray analysis. Genes Immun. 2009; 10:509-516.